CKLF: A Potential Drug Target and Biomarker (G51192)

Target Name: CKLF

NCBI ID: G51192

CKLF

CKLF: A Potential Drug Target and Biomarker

CKLF (Chemokine-like factor (isoform a)) is a protein that is expressed in various cell types, including immune cells, endothelial cells, and epithelial cells. It is a 21-kDa glycoprotein that is characterized by its ability to elicit a strong cellular response to chemokines, such as IL-2, a key regulator of T cell development and function.

The CKLF gene was first identified in 1995 and has since been shown to encode a protein that is highly homologous to other chemokine-like factors, including CKLF-1, CKLF-2, and CKLF-3. These proteins are characterized by their ability to interact with specific chemokines and to regulate the expression of downstream targets, such as IL-2, GATA-3, and NF-kappa-B.

CKLF is a potent regulator of T cell development and function, and it has been shown to play a critical role in the regulation of CD4+ T cell proliferation, differentiation, and selection. CKLF has also been shown to play a role in the regulation of natural killer (NK) cell function, immune surveillance of the skin, and the regulation of inflammation.

CKLF is also a potential drug target and biomarker. CKLF has been shown to be a promising target for small molecule inhibitors, including inhibitors of tyrosine kinase activity and inhibitors of protein-protein interactions. CKLF has also been shown to be a good biomarker for several diseases, including cancer, inflammation, and autoimmune disorders.

One of the challenges in studying CKLF is its complex cellular biology. CKLF is expressed in a variety of cell types and is involved in the regulation of multiple cellular processes. It is expressed in the cytoplasm and has been shown to be involved in the regulation of mitochondrial function, as well as the regulation of cellular signaling pathways, including the T cell signaling pathway.

In addition to its potential as a drug target, CKLF is also a potential biomarker for several diseases. For example, CKLF has been shown to be elevated in the blood and urine of patients with cancer, and it has been used as a biomarker for monitoring the effectiveness of anti-cancer drugs. CKLF has also been shown to be elevated in the blood and urine of patients with inflammatory and autoimmune disorders, and it has been used as a biomarker for monitoring the effectiveness of immunomodulatory drugs.

In conclusion, CKLF is a protein that has the potential to be a drug target and biomarker. Its complex cellular biology and diverse functions make it an attractive target for small molecule inhibitors, and its potential as a biomarker for multiple diseases makes it an important area of research. Further studies are needed to fully understand the role of CKLF in cellular biology and its potential as a drug target and biomarker.

Protein Name: Chemokine Like Factor

Functions: May play an important role in inflammation and regeneration of skeletal muscle (PubMed:11415443). Essential for embryonic development (By similarity)

The "CKLF Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CKLF comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets